Mar 14, 2017
While many institutions have a general research requirement for residents, few have formally defined it. Beginning in 2016, however, all Penn State Health Milton S. Hershey Medical Center OBGYN residents are required to complete an officially sanctioned rotation on a self-developed research question. This rotation is overseen by Timothy Deimling, MD, director of resident research […]
Mar 3, 2017
Dr. Shin Mineishi, director of the blood marrow and transplant program, and his Penn State Cancer Institute colleagues will conduct numerous studies aimed at changing the standard of treatment for acute myelogenous leukemia (AML).
Dr. Raymond Hohl, director, Penn State Cancer Institute, and Jeffrey Neighbors, PhD, assistant professor of pharmacology and medicine at Penn State College of Medicine, are studying whether available cholesterol-modulating medications can play a significant role in treating certain types of cancers.
Penn State Cancer Institute is one of the first in the nation to utilize a new upgrade for Leksell Gamma Knife® Icon radiosurgery, using a motion-tracking mask in addition to the conventional headframe option. The upgrade creates new brain tumor treatment strategies for patients.
Kathryn Schmitz, PhD, MPH, associate director of population sciences, will conduct several studies on the effects of exercise on chemotoxicity in cancer patients as part of Penn State Cancer Institute’s new survivorship program.
Feb 17, 2017
For patients with cervical radiculopathy, total disc replacement using artificial disc devices that have become more widely used during the last 10 years presents a potential advance in treatment.
Treatment options for large talar osteochondral lesions (greater than 1.5 cm) or those that fail to adequately respond to microfracture, have broadened over the last decade, with most procedures directly aimed at hyaline-like cartilage restoration.
Regenerative medicine and tissue engineering for focal chondral defects of the knee joint aim to augment, repair, replace or regenerate the damaged cartilage caused by trauma or the natural aging process. Enrollment is underway at Penn State Health Milton S. Hershey Medical Center for a Phase III clinical trial of an autologous cartilage implant (NOVOCART® 3D, Aesculap Biologics, LLC/B. Braun, Inc.) for the repair of femoral cartilage defects.
When patients need to return to what they consider to be their “normal life” and activity following orthopaedic injuries or surgery, there is little evidence-based guidelines for such assessment.
Oct 28, 2016
Penn State Cancer Institute’s membership in the Big Ten Cancer Research Consortium will help advance the fight against cancer with greater speed and agility. Patients benefit because members institutions share resources for clinical trial resources through the consortium.
